Sep 11, 2023 / 11:00AM GMT
Steve Bersey - H.C. Wainwright & Co. - Analyst
Good day, everyone, and thank you for joining the H.C. Wainwright 25th annual global investment conference. My name's Steve Bersey. I'm an equity research associate at H.C. Wainwright.
So now I'd like to welcome Thomas Equels, President and Chief Executive Officer of AIM ImmunoTech. So I'll turn it over to Thomas.
Thomas Equels - AIM ImmunoTech Inc. - President & CEO
Thank you, Steve, and thank you to H.C. Wainwright for the opportunity to talk about the important programs we have underway at AIM ImmunoTech today. We're a public company, so I ask you to look at our forward-looking statements and also go through our Ks and Qs that are filed to review the risks and disclosure items that you'll find in those documents.
Our drug, Ampligen, which is what our principal drug is today, has a number of very important aspects to it. It has a very wide spectrum of opportunity and impact in different disease areas. We have multiple clinical programs going on right now that are generating data. And so
AIM ImmunoTech Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers